Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.

EBioMedicine · 2017 · PMC5552227 · PMID 28735965

Europe PMC DOI

hedged sentence

0.0380

closest p · 0.8× alpha

0.0380

boldest claim

The sentences

marginally significantP = 0.038actually significant

This difference was marginally significant (Spearman rank ρ = 0.478, P = 0.038, df = 17). 5.3.3.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.